% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Delecluse:298902,
author = {S. Delecluse$^*$ and F. Harder and F. Keller and M. Zeier
and S. Zschäbitz},
title = {{O}nconephrology: {T}he {S}ignificance of {R}enal
{F}unction for the {D}evelopment, {D}iagnosis, and
{T}reatment of {C}ancer.},
journal = {Deutsches Ärzteblatt international},
volume = {121},
number = {24},
issn = {1866-0452},
address = {Köln},
publisher = {Dt. Ärzte-Verl.},
reportid = {DKFZ-2025-00341},
pages = {793-799},
year = {2024},
note = {#EA:D400# /
https://di.aerzteblatt.de/int/archive/article/241946},
abstract = {Modern treatment strategies have markedly improved the
chances of survival for patients with cancer. As the
population ages, cancer is becoming more common, as is
chronic kidney disease (CKD). CKD increases the risk of
cancer; conversely, cancer treatments can cause CKD.This
review is based on publications retrieved by a selective
literature search concerning the epidemiology and
comorbidities of cancer and kidney diseases, the renal side
effects of new anticancer drugs, and the need to consider
renal function in cancer treatment.The prevalence of severe
CKD in Germany is $2.3\%.$ Persons who have CKD, are on
dialysis, or have undergone kidney transplantation are 1.2
to 3.5 times more likely to develop cancer than the general
population. For patients who have CKD or are
dialysis-dependent, the doses of approximately $67\%$ of
anticancer drugs need to be adjusted on the basis of their
glomerular filtration rate and the renally excreted fraction
of the drug. The optimal efficacy of therapeutic drugs, as
well as of those used for diagnostic purposes, and the
minimization of side effects, depend critically on adapted
dosing and on proper timing of administration before or
after dialysis. Modern anticancer drugs can also cause acute
kidney damage (incidence with checkpoint inhibitors:
$2-16\%).Patients$ who have CKD, are on dialysis, or have
undergone kidney transplantation make up a considerable
fraction of persons being treated for cancer, and they need
interdisciplinary treatment.},
subtyp = {Review Article},
keywords = {Humans / Neoplasms: complications / Neoplasms: therapy /
Renal Insufficiency, Chronic: therapy / Renal Insufficiency,
Chronic: complications / Renal Insufficiency, Chronic:
diagnosis / Renal Insufficiency, Chronic: physiopathology /
Antineoplastic Agents: adverse effects / Germany:
epidemiology / Glomerular Filtration Rate / Kidney
Transplantation / Renal Dialysis / Prevalence /
Antineoplastic Agents (NLM Chemicals)},
cin = {D400},
ddc = {610},
cid = {I:(DE-He78)D400-20160331},
pnm = {314 - Immunologie und Krebs (POF4-314)},
pid = {G:(DE-HGF)POF4-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39417369},
doi = {10.3238/arztebl.m2024.0193},
url = {https://inrepo02.dkfz.de/record/298902},
}